

October 6, 2011

Dear Health Care Provider:

RE: FEIBA NF 1000U and 2500U formats now approved with expanded temperature storage of +2°C to +25°C

Baxter Corporation is pleased to advise the hemophilia treatment community that FEIBA NF (ANTI-INHIBITOR COAGULANT COMPLEX, Vapor Heated, Nanofiltered) can now be stored between +2°C to +25°C for its entire shelf life. This change applies retroactively to all FEIBA NF inventory in circulation. **This does not apply to FEIBA VH, which must remain stored at its labeled temperature range of +2°C to +8°C.**

Expanding the storage conditions of FEIBA NF to +2°C to +25°C provides you the flexibility to store product either in a refrigerator or at room temperature. Storage at room temperature frees up refrigerator space and eliminates the need to warm product prior to reconstitution.

Due to the customer preference for FEIBA NF in the 2500U format, it is expected you will see product labeled with the new temperature range (+2°C to +25°C) in October 2011. The 1000U format with the new temperature range on its labels is expected to arrive by March 2012. Baxter will be working closely with Canadian Blood Services to ensure a smooth transition for clinicians and patients.

FEIBA therapy has been trusted for over thirty years, and continues to remain an integral product for the management of bleeds in hemophilia patients with inhibitors. Baxter is committed to the hemophilia community and developed FEIBA NF with expanded temperature storage up to +25°C as the next step in the continuous evolution of FEIBA therapy.

For more information on FEIBA NF 1000U and 2500U packaged with BAXJECT II Hi-Flow and expanded temperature storage between +2°C to +25°C, please contact your local Baxter Specialty Representative or call 1-800-387-8399. Copies of the product monograph can be found at www.baxter.ca.

Sincerely,



Jeff Bakker,
Business Unit Director
BioScience